廣告
香港股市 已收市

  • 恒指

    18,089.93
    +17.03 (+0.09%)
     

  • 國指

    6,477.24
    +12.75 (+0.20%)
     

  • 上證綜指

    2,972.53
    +22.53 (+0.76%)
     

  • 道指

    38,956.95
    -155.21 (-0.40%)
     

  • 標普 500

    5,466.18
    -3.12 (-0.06%)
     

  • 納指

    17,773.79
    +56.13 (+0.32%)
     

  • Vix指數

    12.90
    +0.06 (+0.47%)
     

  • 富時100

    8,221.08
    -26.71 (-0.32%)
     

  • 紐約期油

    80.99
    +0.16 (+0.20%)
     

  • 金價

    2,309.30
    -21.50 (-0.92%)
     

  • 美元

    7.8087
    +0.0001 (+0.00%)
     

  • 人民幣

    0.9302
    +0.0006 (+0.06%)
     

  • 日圓

    0.0484
    -0.0002 (-0.49%)
     

  • 歐元

    8.3417
    -0.0236 (-0.28%)
     

  • Bitcoin

    61,891.57
    +480.13 (+0.78%)
     

  • CMC Crypto 200

    1,280.79
    -2.99 (-0.23%)
     

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock

Zacks Equity Research
·2 分鐘文章

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.

While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.

Is This 1 Momentum Stock a Screaming Buy Right Now?

For momentum investors, upward or downward trends in a stock's price or earnings outlook take precedent, so they'll want to zero in on the Momentum Style Score. This Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

廣告

Halozyme Therapeutics (HALO)

San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company also licenses its novel drug delivery technology, ENHANZE, for subcutaneous (SC) administration of drugs.

HALO boasts a Momentum Style Score of B and VGM Score of A, and holds a Zacks Rank #3 (Hold) rating. Shares of Halozyme Therapeutics has seen some interesting price action recently; the stock is up 3.6% over the past one week and up 15.7% over the past four weeks. And in the last one-year period, HALO has gained 32%. As for the stock's trading volume, 981,556 shares on average were traded over the last 20 days.

Momentum investors don't just pay attention to price changes; positive earnings play a crucial role, too. Two analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.02 to $3.69 per share. HALO boasts an average earnings surprise of 9.4%.

With strong earnings growth, a good Zacks Rank, and top-tier Momentum and VGM Style Scores, investors should think about adding HALO to their portfolios.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Halozyme Therapeutics, Inc. (HALO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research